{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:47Z","timestamp":1792800887227,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.7759\/cureus.115692","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:05:47Z","timestamp":1788411947000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical Utility of Liquid Comprehensive Genomic Profiling in Advanced Lung Adenocarcinoma Complicated by Disseminated Intravascular Coagulation: A Case Report"],"prefix":"10.7759","author":[{"given":"Hiromasa","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanako","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo C","year":"2021","unstructured":"Rolfo C, Mack P, Scagliotti GV, et al.. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021, 16:1647-62. 10.1016\/j.jtho.2021.06.017","journal-title":"J Thorac Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse R","year":"2020","unstructured":"Woodhouse R, Li M, Hughes J, et al.. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One. 2020, 15:e0237802. 10.1371\/journal.pone.0237802","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccm.0000202209.42491.38","article-title":"A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria","volume":"34","author":"Gando S","year":"2006","unstructured":"Gando S, Iba T, Eguchi Y, et al.. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006, 34:625-31. 10.1097\/01.ccm.0000202209.42491.38","journal-title":"Crit Care Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108099","article-title":"Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: an analysis of a nation-wide database","volume":"200","author":"Fujii K","year":"2025","unstructured":"Fujii K, Ueki M, Morishita M, et al.. Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: an analysis of a nation-wide database. Lung Cancer. 2025, 200:108099. 10.1016\/j.lungcan.2025.108099","journal-title":"Lung Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02709-4","article-title":"Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer","volume":"131","author":"Malapelle U","year":"2024","unstructured":"Malapelle U, Leighl N, Addeo A, et al.. Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer. Br J Cancer. 2024, 131:212-9. 10.1038\/s41416-024-02709-4","journal-title":"Br J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100395","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren S","year":"2022","unstructured":"Ren S, Wang J, Ying J, et al.. Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO Open. 2022, 7:100395. 10.1016\/j.esmoop.2022.100395","journal-title":"ESMO Open"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazi\u00e8res J","year":"2013","unstructured":"Mazi\u00e8res J, Peters S, Lepage B, et al.. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013, 31:1997-2003. 10.1200\/JCO.2012.45.6095","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li BT","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, et al.. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022, 386:241-51. 10.1056\/NEJMoa2112431","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto K","year":"2023","unstructured":"Goto K, Goto Y, Kubo T, et al.. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023, 41:4852-63. 10.1200\/JCO.23.01361","journal-title":"J Clin Oncol"},{"key":"ref10","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. (2017). Accessed. September 2, 2026: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/528321-clinical-utility-of-liquid-comprehensive-genomic-profiling-in-advanced-lung-adenocarcinoma-complicated-by-disseminated-intravascular-coagulation-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:05:49Z","timestamp":1788411949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/528321-clinical-utility-of-liquid-comprehensive-genomic-profiling-in-advanced-lung-adenocarcinoma-complicated-by-disseminated-intravascular-coagulation-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.115692","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}